Incyte Corporation (LON:0J9P)
70.10
-0.27 (-0.39%)
At close: Jun 11, 2025
Incyte Revenue
Incyte had revenue of $1.05B USD in the quarter ending March 31, 2025, with 19.53% growth. This brings the company's revenue in the last twelve months to $4.41B, up 17.13% year-over-year. In the year 2024, Incyte had annual revenue of $4.24B with 14.76% growth.
Revenue (ttm)
$4.41B
Revenue Growth
+17.13%
P/S Ratio
2.94
Revenue / Employee
$1.69M
Employees
2,617
Market Cap
10.04B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.24B | 545.57M | 14.76% |
Dec 31, 2023 | 3.70B | 301.01M | 8.87% |
Dec 31, 2022 | 3.39B | 408.37M | 13.67% |
Dec 31, 2021 | 2.99B | 319.57M | 11.98% |
Dec 31, 2020 | 2.67B | 507.94M | 23.53% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Genus | 671.60M |
Incyte News
- 5 days ago - Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 8 days ago - Incyte rises as it will present new data on thrombocythemia asset at conference - Seeking Alpha
- 8 days ago - Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025 - Business Wire
- 9 days ago - 20 stocks primed for rapid growth while trading at half of Nvidia's valuation - Market Watch
- 13 days ago - Incyte: Good Company, But Potentially Overvalued Given Patent Cliffs - Seeking Alpha
- 15 days ago - Incyte to Present at Upcoming Investor Conference - Business Wire
- 27 days ago - Incyte gets expanded FDA approval for Zynyz in anal cancer - Seeking Alpha
- 27 days ago - Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States - Business Wire